COMMUNIQUÉS West-GlobeNewswire
-
SeaStar Medical to Present at Upcoming NobleCon21 Investor Conference
20/11/2025 -
Orbus Therapeutics Highlights Phase 3 STELLAR Clinical Study Results Showing Clinically Meaningful Benefits in Rare Brain Tumor at Society for Neuro-Oncology (SNO) Annual Meeting
20/11/2025 -
RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties
20/11/2025 -
Sharecare selected as exclusive life sciences advertising partner for national point-of-care network CVIEW
20/11/2025 -
New Men’s Health Research from Progyny Challenges Conventional Beliefs about Fertility Knowledge and Action
20/11/2025 -
Omada Health to Participate in Evercore Healthcare Conference
20/11/2025 -
Tekton Research Adds Two New Sites to Expand Neuroscience and General Medicine Capabilities in Key U.S. Markets
20/11/2025 -
Azalea Therapeutics Presents New Preclinical Data Demonstrating Robust In Vivo Generation of TRAC-CAR T Cells Using Enveloped Delivery Vehicles (EDVs)
20/11/2025 -
OneMedNet Accelerates Subscription Revenue Strategy with Industry-Leading Network Expansion: Clinical Exams Increase 37%, Patient Records Grow 38%
20/11/2025 -
MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation
20/11/2025 -
Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference
20/11/2025 -
ICU Medical to Participate at the Piper Sandler 37th Annual Healthcare Conference
20/11/2025 -
Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition
20/11/2025 -
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)
20/11/2025 -
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)
20/11/2025 -
Concept Life Sciences Presents New Data Advancing Neuroinflammation and Neurodegeneration Research at Neuroscience 2025
20/11/2025 -
IMU Biosciences Appoints Dr. Carlos Paya as Non-Executive Director, Strengthening its Board of Directors
20/11/2025 -
Burning Rock Reports Third Quarter 2025 Financial Results
20/11/2025 -
Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates
20/11/2025
Pages